Results 101 to 110 of about 362 (158)

Classification of tau status with machine learning models in amyloid‐positive cohorts

Alzheimer's &Dementia, Volume 22, Issue 8, August 2026.
Abstract INTRODUCTION Although tau positron emission tomography (PET) imaging is effective for staging tau pathology, it is limited clinically by cost and availability. Machine learning models based on magnetic resonance imaging (MRI)– and amyloid PET–derived features may serve as useful screening tools for tau pathology.
Yun‐Chi Lin, Sheng‐Chieh Chiu, Rebecca Massey, Yu‐Hua Dean Fang, for the Alzheimer's Disease Neuroimaging Initiative   +4 more
wiley   +1 more source

Characterization of [18F]SMBT‐1 binding substrates in Alzheimer's disease and related disorders: A postmortem biochemical and immunohistochemical study

Alzheimer's &Dementia, Volume 22, Issue 8, August 2026.
Abstract INTRODUCTION Neuroimaging studies report associations of amyloid beta (Aβ) positron emission tomography (PET) with [18F](S)‐(2‐methylpyrid‐5‐yl)‐6‐[(3‐fluoro‐2‐hydroxy)propoxy]quinoline ([18F]SMBT‐1), a novel reactive astrogliosis surrogate radiotracer with high affinity for monoamine oxidase B (MAO‐B) in Alzheimer's disease (AD).
Eric E. Abrahamson, Julia K. Kofler, Oscar L. Lopez, Anne D. Cohen, Alexandra Gogola, Howard J. Aizenstein, Thomas K. Karikari, Elliott J. Mufson, Victor L. Villemange, Milos D. Ikonomovic   +9 more
wiley   +1 more source

Advancements in Radiopharmaceutical Sciences for Oncology: Current Innovations and Future Challenges

Radiopharmaceutical science has now become a pivotal way of advancing research and therapies within oncology and expanding the future of oncology itself, largely due to dramatic strides in radionuclide development, targeted therapies and theranostics. Much of this scientific progress is now catalyzed by modern developments in radiochemistry, delivery ...
openaire   +1 more source

Plasma p‐tau217 detects Alzheimer's disease co‐pathology in cerebral amyloid angiopathy: Comparison to CSF biomarkers in the ANGMAR cohort

Alzheimer's &Dementia, Volume 22, Issue 8, August 2026.
Abstract INTRODUCTION Cerebral amyloid angiopathy (CAA) frequently co‐occurs with Alzheimer's disease (AD), generating mixed vascular–neurodegenerative phenotypes. Plasma phosphorylated tau (p‐tau)217 is a robust biomarker of AD, but its performance in CAA remains unclear. METHODS We studied 231 participants, including 50 patients with CAA (Boston v2.0)
Aida Fernández‐Lebrero, Joan Jiménez‐Balado, Greta García‐Escobar, José Contador, Isabel Estraguès‐Gázquez, Laia Peraferrer‐Montesinos, Rosa María Manero‐Borràs, Laura Ludovica Gramegna, Marc Viles, Ana Rodríguez Campello, Paula Ortiz‐Romero, Marina de Diego, Marta del Campo, Javier Torres‐Torronteras, Esther Jiménez‐Moyano, Helena Blasco‐Forniés, Marc Suárez‐Calvet, Angel Ois, Albert Puig‐Pijoan, Irene Navalpotro‐Gómez   +19 more
wiley   +1 more source

Synthesis, docking, and preliminary in vitro/in vivo evaluation of MPP-dithiocarbamate-capped silver nanoparticle as dual-imaging agent for 5HT1A

International Journal of Nanomedicine, 2018
Shubhra Chaturvedi,1 Sangeeta Lal,2 Prasenjit Sen,3 Anil K Mishra1 1Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, New Delhi, Delhi, 2Department of Physics, B.S.
Chaturvedi S, Lal S, Sen P, Mishra AK
doaj  

Sex specificity of resistance to caTAUstrophe

Alzheimer's &Dementia, Volume 22, Issue 8, August 2026.
Abstract INTRODUCTION As amyloid beta (Aβ) accumulates, tau pathology spreads beyond medial temporal lobe (MTL) into neocortical (NEO) regions, though some older adults resist this progression, or what we call here “caTAUstrophe.” Given previous evidence of higher tau levels in women, we tested how tau resistance presented in men and women separately ...
Maria Carrigan, Colin Birkenbihl, Hannah M. Klinger, Oliver Langford, Gillian T. Coughlan, Mabel Seto, Jane A. Brown, Annie Li, Madison Cuppels, Michael Properzi, Jasmeer Chhatwal, Julie Price, Aaron Schultz, Dorene Rentz, Rebecca Amariglio, Harm J. Krugers, Rik Ossenkoppele, Keith Johnson, Reisa Sperling, Timothy J. Hohman, Michael Donohue, Rachel F. Buckley   +21 more
wiley   +1 more source

Group‐level versus individualized approaches for capturing tau PET changes and clinical progression in Alzheimer's disease

Alzheimer's &Dementia, Volume 22, Issue 8, August 2026.
Abstract INTRODUCTION Quantification approaches based on group‐level regions of interest (ROIs) are widely used for evaluating tau positron emission tomography (PET) and clinical progression in Alzheimer's disease (AD), but we hypothesize that personalized approaches better capture inter‐individual heterogeneity.
Hannah de Bruin, Colin Groot, Zeyu Zhu, Elsmarieke van de Giessen, Sergey Shcherbinin, Vikas Kotari, Diana O. Svaldi, Yolande A. L. Pijnenburg, Emma M. Coomans, Rik Ossenkoppele, Nicolai Franzmeier, for the Alzheimer's Disease Neuroimaging Initiative (ADNI)   +11 more
wiley   +1 more source

The role of IAEA in the Development of Radiopharmaceutical Sciences with Focus on Alpha Emitters [PDF]

Journal of Medical Imaging and Radiation Sciences, 2019
Amirreza Jalilian, Joao Alberto Osso, Aruna Korde, Starovoitova Valeriia   +3 more
openaire   +1 more source

APOE and genetic risk variants influence Alzheimer's disease onset in carriers of an extra copy of APP, with and without Down syndrome

Alzheimer's &Dementia, Volume 22, Issue 8, August 2026.
Abstract INTRODUCTION An extra copy of the amyloid precursor protein (APP) gene causes autosomal dominant Alzheimer's disease (AD) and AD in Down syndrome (DS), but the factors underlying variability in age at onset (AAO) remain unclear. We investigated whether sporadic AD risk variants modify AAO. METHODS We analyzed clinical and genetic data from 100
Joan Groeneveld, Danna Perlaza, Clàudia Olivé, Lou Grangeon, Niccolo Tesi, Aude Nicolas, Chenyang Jiang, Itziar de Rojas, David Wallon, Stéphane Rousseau, Marta Rovira, Diego Real de Asúa, Fernando Moldenhauer, Ruihao Mu, Kévin Cassinari, Aline Zarea, Joaquim Aumatell Escabias, Jean‐Charles Lambert, Yolande A. L. Pijnenburg, Marc Hulsman, Everard G. B. Vijverberg, Johannes Levin, Mathias Jucker, Eric McDade, Juan Fortea, Henne Holstege, Flora H. Duits, Lisa Vermunt, Maulikkumar Patel, Matthew Johnson, Alan E. Renton, Alison M. Goate, Carlos Cruchaga, Cyril Pottier, Maria Victoria Fernandez, Olivia Belbin, Gael Nicolas, Oriol Dols‐Icardo, Sven J. van der Lee, Dominantly Inherited Alzheimer Network   +39 more
wiley   +1 more source

Optimized plasma p‐tau217 and p‐tau217/Aβ42 cutoffs enhance detection of pre‐clinical Alzheimer's disease across diverse participants

Alzheimer's &Dementia, Volume 22, Issue 8, August 2026.
Abstract INTRODUCTION Plasma p‐tau217 and p‐tau217/Aβ42 reliably identify non‐Hispanic White individuals with symptomatic and pre‐clinical AD. However, performance across ethnoracially diverse groups remains unknown. METHODS Cognitively normal Black, Hispanic, and non‐Hispanic White participants completed cognitive evaluations, brain magnetic resonance
Yoav D Piura, Paula A Aduen, Leah Schecter, Manoj K Jain, Alicia Algeciras‐Schimnich, Daniel J Figdore, Joshua Bornhorst, Ronald C Petersen, Clifford R Jack Jr, Neill R Graff‐Radford, Christian Lachner, Gregory S Day   +11 more
wiley   +1 more source